Novavax, Inc.
NVAX scores 59.6 on the Conservative profile, blending a fundamental score (80% weight, emphasizing quality and stability (84% of fundamental weight)) with a machine-learning signal (20% weight) trained on 82 features across 30 years of data.
Minor adjustments (-2.4 points) applied. NVAX's rank of #370 primarily reflects its factor profile relative to the conservative weight vector.
These features are direct inputs to the machine learning model. The model was trained on these signals alongside 100 features (including 12 momentum/technical indicators) to produce the ML percentile score.
| Stock | Score | P/E | Rev Growth | Margin | Mkt Cap |
|---|---|---|---|---|---|
| NVAX | 59.6 | 4.4 | 22.6% | 32.1% | $1.8B |
| INCY | 89.9 | 15.8 | 21.2% | 25.0% | $19.6B |
| GMAB | 86.1 | 13.1 | 22.8% | 36.4% | $17.9B |
| CPRX | 83.7 | 13.7 | 23.5% | 37.6% | $3.0B |
| ASND | 78.3 | 16.6 | 98.0% | -31.7% | $13.8B |
| EXEL | 78.3 | 15.1 | 7.0% | 33.7% | $11.9B |
| VRTX | 78.2 | 32.1 | 8.9% | 32.9% | $121.8B |
| NBIX | 75.1 | 26.5 | 21.4% | 16.7% | $13.1B |
| RPRX | 75.0 | 25.1 | 5.1% | 32.4% | $19.3B |
| HOLX | 74.8 | 31.1 | 1.7% | 13.8% | $16.8B |
| AMGN | 74.2 | 26.0 | 10.0% | 21.0% | $204.8B |
| ARGX | 73.7 | 35.1 | 78.6% | 38.0% | $47.4B |
| REGN | 73.0 | 19.4 | 1.0% | 31.4% | $80.2B |
| ALKS | 72.9 | 16.5 | -6.4% | 23.9% | $5.0B |
| ISRG | 72.7 | 61.7 | 20.5% | 28.4% | $180.9B |
| KRYS | 71.5 | 41.4 | 473.0% | 30.7% | $7.9B |
| Sector Average | 36.6 | 41.9 | 161.5% | -3292.7% | โ |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Stock is in an uptrend above the 200-day moving average. This is the stage where institutional accumulation typically occurs. The 50-day SMA provides support.
| Metric | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|
| Revenue | $70M | $239M | $667M | $88M |
| Gross Profit | $49M | $225M | $653M | $52M |
| Operating Income | $-178M | $106M | $516M | $-131M |
| Net Income | $-202M | $107M | $519M | $-81M |
| EPS (Diluted) | $-1.25 | $0.60 | $2.93 | $-0.51 |
| Gross Margin | 69.5% | 94.1% | 97.9% | 58.5% |
| Operating Margin | -252.7% | 44.2% | 77.3% | -148.4% |
| Net Margin | -287.3% | 44.5% | 77.8% | -91.8% |
| Year | Low | High | Range | Status |
|---|---|---|---|---|
| 2021 | $117.12 | $277.80 | 81.4% | Wide |
| 2022 | $8.75 | $145.20 | 177.3% | Wide |
| 2023 | $4.80 | $13.70 | 96.2% | Wide |
| 2024 | $3.53 | $23.86 | 148.4% | Wide |
| 2025 | $5.01 | $11.55 | 79% | Wide |
Scores are generated by a multi-stage ML pipeline combining fundamental analysis, ensemble predictions, and structural risk signals. All data is for research purposes only and does not constitute financial advice. Past performance does not guarantee future results.